Molecular Pathology

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Maillard, M
Right arrow Articles by Tatoud, R
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Maillard, M
Right arrow Articles by Tatoud, R
J Clin Pathol: Mol Pathol 2001; 54:275-280
© 2001 Journal of Clinical Pathology

Differential expression of the ccn3 (nov) proto-oncogene in human prostate cell lines and tissues

M Maillard1, B Cadot*,2, R Y Ball3, K Sethia3, D R Edwards1, B Perbal2 and R Tatoud1

1 School of Biological Sciences, University of East Anglia, Norwich NR4 7TJ, UK
2 UFR de Biochimie, Université Paris 7 - D. Diderot, 2 Place Jussieu, 75 005 Paris, France
3 Norfolk and Norwich Health Care NHS Trust, Norwich, NR1 3SR, UK

Correspondence: Dr Tatoud, Biomedical Research Centre, University of Dundee, Ninewells Hospital (level 5), Dundee DD1 9SY, UK roger{at}tatoud.fsnet.co.uk

Aims—To investigate the expression of the human ccn3 (hccn3; nov) proto-oncogene, a member of the CCN family of proteins, in prostate epithelial cells and prostate tissue samples.

Methods—Normal adult prostate luminal epithelial cells immortalised by SV40 large T (PNT1A and PNT1B), metastatic tumours (LNCaP, DU-145, and PC-3), and prostate tissue samples from patients with benign prostatic hyperplasia (BPH) and prostatic adenocarcinoma were used. hccn3 (nov) mRNA was measured by the reverse transcription polymerase chain reaction (RT-PCR) and hCCN3 (NOV) protein expression was determined by immunochemistry.

Results—hccn3 (nov) RNA values were higher in PC-3 cells than in the other prostate cell lines. The immortalised normal cell lines either did not express hccn3 (nov) RNA (PNT1B) or expressed very low amounts (PNT1A). BPH samples expressed variable amounts of hccn3 (nov) RNA. With the use of immunocytochemistry, all cell lines except PNT1A and PNT1B were shown to contain hCCN3 (NOV) protein. hCCN3 (NOV) was localised mainly in the epithelial compartment of BPH and adenocarcinoma samples, and there was evidence of luminal secretion.

Conclusion—The overexpression of hccn3 (nov) RNA in cancer cell lines compared with other cell lines and its epithelial localisation in human prostate samples are consistent with a role for hCCN3 (NOV) in prostatic tumorigenesis.

Key Words: prostate tumour • human NOV • CCN




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
C. J.M. Best, J. W. Gillespie, Y. Yi, G. V.R. Chandramouli, M. A. Perlmutter, Y. Gathright, H. S. Erickson, L. Georgevich, M. A. Tangrea, P. H. Duray, et al.
Molecular Alterations in Primary Prostate Cancer after Androgen Ablation Therapy
Clin. Cancer Res., October 1, 2005; 11(19): 6823 - 6834.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. G. Lin, C.-C. Chen, S.-J. Leu, T. M. Grzeszkiewicz, and L. F. Lau
Integrin-dependent Functions of the Angiogenic Inducer NOV (CCN3): IMPLICATION IN WOUND HEALING
J. Biol. Chem., March 4, 2005; 280(9): 8229 - 8237.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. T. Fu, J. F. Bechberger, M. A. Ozog, B. Perbal, and C. C. Naus
CCN3 (NOV) Interacts with Connexin43 in C6 Glioma Cells: POSSIBLE MECHANISM OF CONNEXIN-MEDIATED GROWTH SUPPRESSION
J. Biol. Chem., August 27, 2004; 279(35): 36943 - 36950.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
R. L. Stephen, M. C. U. Gustafsson, M. Jarvis, R. Tatoud, B. R. Marshall, D. Knight, E. Ehrenborg, A. L. Harris, C. R. Wolf, and C. N. A. Palmer
Activation of Peroxisome Proliferator-Activated Receptor {delta} Stimulates the Proliferation of Human Breast and Prostate Cancer Cell Lines
Cancer Res., May 1, 2004; 64(9): 3162 - 3170.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
H. Thibout, C. Martinerie, C. Creminon, F. Godeau, P. Boudou, Y. Le Bouc, and M. Laurent
Characterization of Human NOV in Biological Fluids: An Enzyme Immunoassay for the Quantification of Human NOV in Sera from Patients with Diseases of the Adrenal Gland and of the Nervous System
J. Clin. Endocrinol. Metab., January 1, 2003; 88(1): 327 - 336.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Y. Hu, J. E. Ippolito, E. M. Garabedian, P. A. Humphrey, and J. I. Gordon
Molecular Characterization of a Metastatic Neuroendocrine Cell Cancer Arising in the Prostates of Transgenic Mice
J. Biol. Chem., November 8, 2002; 277(46): 44462 - 44474.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pathol.Home page
C L Li, V Martinez, B He, A Lombet, and B Perbal
A role for CCN3 (NOV) in calcium signalling
Mol. Pathol., August 1, 2002; 55(4): 250 - 261.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Molecular Pathology Journal of Clinical Pathology
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2001 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.